OTCPK:IOBC.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. More Details


Snowflake Analysis

Mediocre balance sheet and overvalued.


Similar Companies

Share Price & News

How has Ion Beam Applications's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IOBC.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

11.8%

IOBC.F

-2.0%

US Medical Equipment

-1.9%

US Market


1 Year Return

-28.4%

IOBC.F

14.7%

US Medical Equipment

13.1%

US Market

Return vs Industry: IOBC.F underperformed the US Medical Equipment industry which returned 14.6% over the past year.

Return vs Market: IOBC.F underperformed the US Market which returned 12.7% over the past year.


Shareholder returns

IOBC.FIndustryMarket
7 Day11.8%-2.0%-1.9%
30 Day42.4%0.2%-2.9%
90 Day44.4%13.1%8.2%
1 Year-28.4%-28.4%15.7%14.7%15.7%13.1%
3 Year-63.0%-63.0%71.6%67.2%38.4%29.1%
5 Year-60.7%-60.7%145.9%127.4%89.3%68.0%

Price Volatility Vs. Market

How volatile is Ion Beam Applications's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Ion Beam Applications undervalued compared to its fair value and its price relative to the market?

337.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: IOBC.F ($12.53) is trading above our estimate of fair value ($9.2)

Significantly Below Fair Value: IOBC.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IOBC.F is poor value based on its PE Ratio (337.3x) compared to the US Medical Equipment industry average (48.3x).

PE vs Market: IOBC.F is poor value based on its PE Ratio (337.3x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: IOBC.F's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: IOBC.F is good value based on its PB Ratio (3x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Ion Beam Applications forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-28.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IOBC.F's earnings are forecast to decline over the next 3 years (-28.4% per year).

Earnings vs Market: IOBC.F's earnings are forecast to decline over the next 3 years (-28.4% per year).

High Growth Earnings: IOBC.F's earnings are forecast to decline over the next 3 years.

Revenue vs Market: IOBC.F's revenue (5% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: IOBC.F's revenue (5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IOBC.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Ion Beam Applications performed over the past 5 years?

-48.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IOBC.F has a large one-off gain of €13.0M impacting its June 30 2020 financial results.

Growing Profit Margin: IOBC.F became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IOBC.F's earnings have declined by 48.8% per year over the past 5 years.

Accelerating Growth: IOBC.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IOBC.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: IOBC.F's Return on Equity (0.9%) is considered low.


Next Steps

Financial Health

How is Ion Beam Applications's financial position?


Financial Position Analysis

Short Term Liabilities: IOBC.F's short term assets (€337.7M) exceed its short term liabilities (€260.3M).

Long Term Liabilities: IOBC.F's short term assets (€337.7M) exceed its long term liabilities (€82.5M).


Debt to Equity History and Analysis

Debt Level: IOBC.F's debt to equity ratio (63.7%) is considered high.

Reducing Debt: IOBC.F's debt to equity ratio has increased from 23.5% to 63.7% over the past 5 years.

Debt Coverage: IOBC.F's debt is well covered by operating cash flow (116.2%).

Interest Coverage: Insufficient data to determine if IOBC.F's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Ion Beam Applications's current dividend yield, its reliability and sustainability?

0.75%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: IOBC.F's dividend (0.75%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.71%).

High Dividend: IOBC.F's dividend (0.75%) is low compared to the top 25% of dividend payers in the US market (4.88%).


Stability and Growth of Payments

Stable Dividend: IOBC.F is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: IOBC.F is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: IOBC.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IOBC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Olivier Legrain (52 yo)

8.33yrs

Tenure

€575,486

Compensation

Mr. Olivier Legrain has been the Chief Executive Officer, President and Executive Director at Ion Beam Applications, S.A. since May 9, 2012 and served as its President of Molecular Medicine at Ion Beam App ...


CEO Compensation Analysis

Compensation vs Market: Olivier's total compensation ($USD673.87K) is below average for companies of similar size in the US market ($USD2.02M).

Compensation vs Earnings: Olivier's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Pierre Mottet
Chairman of The Board7.33yrs€67.50kno data
Olivier Legrain
CEO, President8.33yrs€575.49kno data
Yves Jongen
Founder29.33yrs€456.00kno data
Frédéric Nolf
Chief Human Resources & Sustainability Officer10.67yrsno datano data
Jean-Marc Bothy
President of IBA Dosimetry2.58yrsno datano data
Soumya Chandramouli
Chief Financial Officer4.25yrsno datano data
Thomas Ralet
Vice-President of Corporate Communicationno datano datano data
Matthias Dierl
Chief Medical Physicist of Radiation Therapyno datano datano data
Marc Van der Burght
Executive Vice President of Proton Therapy Installationno datano datano data

6.3yrs

Average Tenure

54yo

Average Age

Experienced Management: IOBC.F's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pierre Mottet
Chairman of The Board7.33yrs€67.50kno data
Olivier Legrain
CEO, President8.33yrs€575.49kno data
Yves Jongen
Founder29.33yrs€456.00kno data
Marcel Miller
Independent Director9.33yrs€37.20kno data
Richard Hausmann
Directorno datano datano data
Sybille Van den Hove
Independent Director5.33yrs€31.80kno data
Hedvig Hricak
Independent Director3.33yrs€24.00kno data
Christine Dubus
Directorno datano datano data

7.8yrs

Average Tenure

60yo

Average Age

Experienced Board: IOBC.F's board of directors are considered experienced (7.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ion Beam Applications SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ion Beam Applications SA
  • Ticker: IOBC.F
  • Exchange: OTCPK
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €299.561m
  • Listing Market Cap: €350.775m
  • Shares outstanding: 29.66m
  • Website: https://www.iba-worldwide.com

Number of Employees


Location

  • Ion Beam Applications SA
  • 3, chemin du Cyclotron
  • Louvain-la-Neuve
  • Walloon Brabant
  • 1348
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IOBC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 1998
IBABENXTBR (Euronext Brussels)YesOrdinary SharesBEEURJun 1998
IOBDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 1998
0GZKLSE (London Stock Exchange)YesOrdinary SharesGBEURJun 1998
IBABBBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEURJun 1998

Biography

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through P ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/23 05:32
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.